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Abstract  
Vascular endothelial growth factor receptors (VEGFRs) are part of the evolutionarily 
conserved VEGF signalling pathways that regulate the development and maintenance 
of the body’s cardiovascular and lymphovascular systems. VEGFR3, encoded by the 
FLT4 gene, has an indispensable and well-characterised function in development and 
establishment of the lymphatic system. Autosomal dominant VEGFR3 mutations, that 
prevent the receptor functioning as a homodimer, cause one of the major forms of 
hereditary primary lymphoedema; Milroy disease. Recently, we and others have 
shown that FLT4 variants, distinct to those observed in Milroy disease cases, 
predispose individuals to Tetralogy of Fallot, the most common cyanotic congenital 
heart disease, demonstrating a novel function for VEGFR3 in early cardiac 
development. Here, we examine the familiar and emerging roles of VEGFR3 in the 
development of both lymphovascular and cardiovascular systems, respectively, 
compare how distinct genetic variants in FLT4 lead to two disparate human conditions, 
and highlight the research still required to fully understand this multifaceted receptor.  
 
key words: angiogenesis and lymphangiogenesis; primary lymphoedema; heart 
development; vascular endothelial growth factor receptors; congenital heart disease 
Manuscript
 
 
   
 
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of 
Cardiology.  
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and 
reproduction in any medium, provided the original work is properly cited. 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/advance-article/doi/10.1093/cvr/cvaa291/5926966 by guest on 21 O
ctober 2020
2 
 
1. Introduction 
The two central components of the circulatory system are the cardiovascular, 
comprised of the heart, blood vessels and blood; and the lymphovascular, comprised 
of vessels, lymph nodes and lymph. The majority of interstitial fluid, consisting of the 
filtered blood plasma from between cells, enters the initial capillaries of the 
lymphovascular system where it becomes lymph.1 Whilst the cardiovascular system is 
a closed network of blood vessels and capillaries, the lymphatic system is an open 
system, which by a series of blind-ended capillaries, vessels, trunks and ducts returns 
the drained fluid back into the bloodstream at the subclavian vein.2  
 
Diseases of the cardiovascular system are the leading cause of death globally.3 Of 
these, congenital heart disease (CHD) is the most common birth defect that arises due 
to abnormalities in heart and great vessel development early during embryonic life.4 
Disorders of lymphatic vessels, such as lymphoedema, lymphangitis, 
lymphangiectasia and lymphatic malformations, are less common than cardiovascular 
diseases, but can have severe effects on well-being and life expectancy.5 
Lymphoedemas can be primary, caused by genetic factors, or secondary, as the result 
of accident or other disease.  
 
Vascular endothelial growth factor receptors (VEGFRs) are essential in orchestrating 
the development and lifelong maintenance of both cardiovascular and lymphovascular 
systems. Their aberrant expression or dysfunction is associated with a range of human 
diseases (Table 1). VEGFR signalling is highly complex; the reader is referred to 
excellent recent reviews dealing in particular with VEGFR1 and VEGFR2 signalling. 
In this review we will focus on the established and emerging roles of VEGFR3, 
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encoded by the FLT4 gene in humans and the Vegfr3 gene in the mouse, in both 
lymphatic and cardiac congenital disorders. By exploring the cell biology, animal 
models, and human conditions associated with Vegfr3/FLT4, we aim to highlight the 
diverse developmental and physiological roles played by the receptor. 
 
 
2. Vascular endothelial growth factor receptors and their ligands 
2.1. Signalling via VEGFR1 and VEGFR2 
Since the discovery of VEGF over thirty years ago by Leung et al.6 the variety of roles 
VEGFs and VEGFRs play in development and maintenance of the vasculature and 
their function in health and disease have been extensively studied. We commence 
with a necessarily brief overview of the broader signalling pathway, directing the 
reader to appropriate authoritative articles, to provide a degree of context for our more 
in-depth consideration of VEGFR3/FLT4. The family consists of five peptide ligands 
(VEGFA-D and placental growth factor) and three receptors (VEGFR1-3), which can 
act together or antagonistically during development and throughout life in the 
circulatory system but also in other tissues (Figure 1).7, 8 VEGFRs all homodimerise; 
in addition VEGFR2 can heterodimerise with either VEGFR1 or VEGFR3, resulting in 
receptor activation. VEGFRs can also interact with distinct coreceptors; and different 
VEGF cleavage products and isoforms add further complexity to the regulation of 
VEGFR signalling.8, 9  
 
VEGFRs are receptor tyrosine kinases that associate as homo- or heterodimers at the 
plasma membrane. They have an extracellular region comprising of seven 
immunoglobulin-like domains where their respective ligands bind, in addition to a 
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transmembrane region and an intracellular kinase domain. Ligand binding to VEGFRs 
promotes dimerisation and auto- or transphosphorylation of tyrosine residues in their 
intracellular regions. The phosphotyrosines then act as docking sites for cytoplasmic 
signalling molecules, which, depending on biological context, activate distinct 
downstream signalling cascades that allow them to mediate their physiological 
functions.9, 10 Evidence also suggests that c-SRC-mediated VEGFR2 activation can 
occur in the absence of ligand, inducing ligand-independent phosphorylation and 
downstream signalling of VEGFR2.11 
 
Homodimeric VEGFR2 is a key regulator of angiogenesis; endothelial cell proliferation 
and survival; and vascular permeability in response to the canonical VEGF ligand 
VEGFA.7 VEGFR1 has a key function antagonising VEGFR2 signalling mediated by 
a greater binding affinity for VEGFA that allows for sequestration of the ligand.12 
VEGFR1 demonstrates immunomodulatory functions, driving monocyte and 
macrophage chemotaxis.13 VEGFR1/VEGFR2 heterodimers orchestrate endothelial 
cell migration and tube formation.14 VEGFR2 also cooperates with VEGFR3 during 
cell tip specification in angiogenic sprouting.15 VEGFA can also interact directly with 
the PDGF (platelet-derived growth factor) signalling pathway during mesenchymal cell 
proliferation and migration.16, 17 
 
Following ligand binding, VEGFRs are rapidly internalised into endocytotic vesicles as 
a means to control their activity. Vesicular VEGFRs can still actively signal, be recycled 
back to the plasma membrane, targeted for lysosomal degradation or returned to the 
Golgi maturation pathway18. The internalisation process is highly important for the 
control of VEGF/VEGFR signalling, for example, internalisation of VEGFR2 is required 
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for ERK (extracellular signal-regulated kinase) and AKT activation.9 Post-translational 
modification, cleavage or degradation have also been described as regulatory 
mechanisms for controlling signalling through VEGFRs.19  
 
Due to their ability to control and stimulate growth of new vasculature, the VEGFR1 
and VEGFR2 signalling pathways participate in a wide variety of physiological and 
pathological processes that lie beyond the scope of this focused review. For excellent 
reviews providing greater detail regarding the biology of the VEGF ligand family, their 
dysfunction in disease, and their therapeutic potential see Karaman et al., 20188; Park 
et al., 201820 and Uccelli et al., 2019.21 The role of VEGFRs in tumour angiogenesis22-
25, Alzheimer’s disease26, and vascular dysfunction27-31 has also been reviewed. 
 
2.2. Signalling via VEGFR3 homodimers 
VEGFR3 is a key regulator of lymphatic system development and establishment. 
Unlike the other VEGFRs, VEGFR3 is proteolytically cleaved within its fifth 
extracellular immunoglobulin-like domain and the two resulting peptides are then 
disulphide bonded as part of its maturation in the extracellular matrix (Figure 1). The 
mechanism and function of this cleavage step have not been extensively studied but 
is thought to be important for ligand binding and stability of the receptor when at the 
cell membrane.32  
 
Structural examination of VEGFR3 ligand binding propensity identified the first three 
immunoglobulin-like domains as the direct interaction site for VEGFC; however, the 
majority of the extracellular region is required for proper ligand-induced receptor 
activation and subsequent downstream signalling (Figure 2a).32, 33 In humans, at least 
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three isoforms of VEGFR3 are expressed that function differently and have distinct 
physiological roles. The full-length isoform is well-characterised and discussed 
hereafter; a second isoform is shorter from the C-terminus by sixty-five amino acids 
including tyrosine residues whose phosphorylation can function to activate signalling 
downstream of the receptor. A third VEGFR3 isoform lacks a much larger C-terminal 
coding region including the transmembrane domain, and is a secreted soluble protein 
that acts to sequester VEGFC in the retina.34-36   
 
The receptor is expressed in lymphatic endothelial cells (LECs) where it acts as a 
homodimer that responds to the extracellular ligands VEGFC and VEGFD.37, 38 The 
binding of the ligands activates the intracellular kinase domains which then trans-
autophosphorylate each other.39 The specific phosphotyrosine residues of VEGFR3 
that are required for activation of intracellular signalling pathways are located in the 
juxtamembrane domain, the kinase domain and C-terminal tail.39 Trans-
autophosphorylation results in recruitment of adaptor proteins such as CRK (CT10 
regulator of kinase), SHC (SRC homology domain containing) and GRB2 (growth 
factor receptor-bonus protein 2), which in conjunction with phosphatidylinositol-3-
kinase (PI3K) activate downstream signalling pathways that include the conserved 
PI3K/MAPK (mitogen-activated protein kinase)-associated family members AKT, 
ERK1/2 and JNK (c-Jun N-terminal kinase).39, 40  
 
VEGFC is required for lymphatic development and the VEGFR3/VEGFC signalling 
axis is particularly important during the expansion of the lymphatic system when LECs 
start budding off from the cardinal vein.41 Paracrine secretion of VEGFC provides a 
chemogradient in areas of active lymphangiogenesis and lymphatic vessel 
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development can therefore be controlled spatially and temporally.42 VEGFC is only 
active after proteolytic processing and CCBE1 (collagen and calcium binding 
extracellular growth factor domain 1) is crucial for the immobilisation of pro-VEGFC 
enabling CCBE1’s cofactor ADAMTS3 (a disintegrin and metalloproteinase with 
thrombospondin motifs 3) to proteolytically activate the ligand.43 Due to their essential 
role in VEGFC processing, mutations in human CCBE1, ADAMTS3 and VEGFC have 
been shown to cause various forms of primary lymphoedema.44-46 
   
In order to maintain their endothelial cell identity during embryogenesis, LECs employ 
a positive feedback loop whereby VEGFR3 signalling maintains the expression of the 
transcription factor PROX1 (homeobox prospero-like 1), which in turn regulates 
expression of the receptor.47, 48 Both PROX1 and the transcription factor FOXC2 
(forkhead box protein C2) play a role in the proper formation, location and function of 
the lymphatic valves in a process requiring VEGFR3 activation and its subsequent 
degradation through an EPSIN-mediated mechanism.49-51  
 
The transcription factor ETV2 is known to have key roles in early developmental 
processes and is required for lymphangiogenesis through direct regulation of VEGFR3 
expression.52 Similarly, integrin-linked kinase (ILK) is known to play a role in regulating 
VEGFR3 signalling during lymphatic vascular growth.53 Signalling downstream of 
VEGFR3 in LECs can be inhibited by vascular endothelial phosphatase; the only 
evidenced regulatory VEGFR3 phosphatase identified thus far.54 VEGFR3 expression 
has also been shown in nonvascular cell types including osteoblasts, neural progenitor 
cells and macrophages.55-57 
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2.3. Signalling via VEGFR3 heterodimers 
As previously mentioned, VEGFR3 is able to function as a heterodimer with VEGFR2 
as a receptor for VEGFC ligand binding during angiogenesis and haematopoiesis 
(Figure 3a). In a culture of murine aortic mesoderm explants from Vegfr3 knockout 
embryos, vascular bed formation was enhanced compared to wild type and 
heterozygous embryos, and haematopoiesis severely diminished. It has been 
postulated that in the absence of VEGFR3, a higher abundance of VEGFC is free to 
signal through VEGFR2, leading to disruption of angiogenesis and blood cell formation 
during embryogenesis.58 VEGFR2-positive cells derived from embryonic stem cells 
serve as vascular progenitors that differentiate into endothelial cells upon VEGFA 
stimulation. Likewise, VEGFC is also able to stimulate endothelial differentiation into 
LECs when VEGFR2 and VEGFR3 act in a heterodimeric manner.59  
 
Neuropilin 2 (NRP2) has also been shown to be a coreceptor for both VEGFR2 and 
VEGFR3 and can act in response to VEGFA and VEGFC (Figure 3b). Expression of 
NRP2 promotes survival of endothelial cells in response to both ligands and promotes 
migration of human microvascular endothelial cells.60 Lymphatic system vascular 
sprouting can be mediated by VEGFR3 and NRP2 interacting at the plasma 
membrane in response to VEGFC. This process is independent of Vegfr2 since 
Vegfr2+/-/Nrp2+/- but not Vegfr3+/-/Nrp2+/- double heterozygous mice have normal 
lymphatic vessel sprouting during development and lymph vessel branching later in 
life.61 The hypoxia regulated transmembrane protein CLP24 (claudin-like protein 
24kDa) is also required for lymphatic vessel sprouting through interaction with 
VEGFR2 and VEGFR3 promoting downstream phosphorylation of the transcription 
factor CREB (cyclic adenosine monophosphate response element-binding protein).62 
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As mentioned previously, there is some evidence that dimerisation of the VEGFRs can 
occur in the absence of ligand with reduced downstream signalling.10 However, it has 
been shown that both VEGFA and VEGFC strongly promote heterodimerisation of 
VEGFR2 and VEGFR3 in both developing blood vessels and in early lymphatic 
progenitor cells.63, 64 The presence of ligand also leads to spatial aggregation of dimers 
in the leading tip of growing angiogenic sprouts.15, 63, 64 
 
During angiogenesis, endothelial cells undergo specification to tip or stalk cells of 
newly developing blood vessels.65 Endothelial-specific knockout of Vegfr3 in mice led 
postnatally to excessive angiogenic sprouting and branching whilst decreasing the 
level of Notch signalling.66 VEGFR3 regulates angiogenic sprouting even in the 
presence of VEGFR2 inhibitors, suggesting this function can be independent of 
VEGFR2-VEGFR3 cooperation.67, 68 VEGFR3 regulation by the NOTCH pathway has 
also been shown to facilitate angiogenesis without the requirement of VEGFR2 
signalling, however, in the retina VEGFR2 is explicitly required for this process.69  
 
VEGFR2 and VEGFR3 have also been identified as components of a complex that 
mediates the response of vascular endothelial cells to fluid sheer stress during 
development and angiogenesis. In this role VE-cadherin acts as an adaptor by binding 
directly to the transmembrane domain of both VEGFR2 and VEGFR3. In vivo Vegfr3 
was directly shown to contribute to the response of flow in the aortic endothelium.70 
Interestingly, evidence suggests the role of Vegfr3 as part of a mechanosensitive 
complex in blood vessel formation is ligand-independent, this is thought to be due to 
its ability to modulate Vegfr2 signalling.71 VEGFR3 signalling can also be mediated 
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through integrin/SRC; this however induces a different phosphorylation pattern to that 
induced by VEGFC and VEGFD.72 This indicates ligand independent functions for 
VEGFR3 and adds to the complexity of the VEGFR3 signalling system.66, 73  
 
 
3. VEGFR3 signalling and congenital lymphovascular malformation 
3.1. Normal development of the lymphatic system 
The lymphatic vasculature is an essential part of the body’s circulatory systems with 
roles in immune surveillance, fat absorption and fluid homeostasis. 
Lymphangiogenesis refers to the appropriate production and maintenance of a 
functioning lymphatic system in the vascularised tissues of the body throughout life.74, 
75 
 
In brief, the first appearance of the lymphatic system in mice is approximately E9.5 
when endothelial cells of the cardinal vein differentiate to the LEC lineage.76, 77 At 
around E10.5 these cells bud and emerge from the cardinal and intersomitic veins 
and, following migration, form a primitive lymphatic plexus and lymph sacs. Afferent 
and efferent lymph vessels then proceed to emerge throughout the tissues of the 
developing embryo forming distinct lymph nodes and producing lymphovenous valves 
for regulation of fluid movement between the lymphatic and cardiovascular systems.77 
At approximately E15 the lymphatic system undergoes maturation and remodelling at 
which point lymphatic valves are formed. Their function is to control unidirectional 
movement of lymph.2  
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An important role of the lymphatic system is to maintain body fluid homeostasis by 
draining plasma filtrate from the interstitium, but it is also intrinsically linked to immune 
cell function since LECs can secrete chemokines and thereby recruit immune cells 
and transport them into lymph nodes during inflammatory immune responses.78 
Lymphatic vessels in the gut (also known as lacteals) are responsible for the 
absorption of dietary fat which is then transported as chyle up through the thoracic 
duct into the venous circulation.79, 80 Lymphatic development is a very complex 
process and the list of genes and gene products involved is rapidly expanding. For a 
more comprehensive overview of the known cellular and molecular processes 
controlling the development of the lymphatic system during embryogenesis the readier 
is directed to some excellent reviews.41, 42, 75, 81, 82 
 
3.2. Dominant negative VEGFR3 mutations in Milroy disease 
Lymphoedema is caused by impaired drainage or transport of interstitial fluid which 
leads to a build-up of lymph, resulting in chronic swelling.83 It typically affects the limbs 
but may involve any body site also within the inner body cavities, for example pleural 
and pericardial effusions or ascites. Lymphoedema can be discomforting and 
associated with high morbidity from loss of mobility and recurrent infections.84 There 
are two main types of lymphoedema: primary lymphoedema, which is the result of an 
underlying genetic abnormality, and secondary lymphoedema, which arises due to 
damage to the lymphatic system as a result of trauma, infection or following surgery 
or radiotherapy.5  
 
Primary lymphoedema is a highly heterogenous condition with many different genetic 
causes, some as autosomal dominant traits, such as Milroy disease or lymphoedema 
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distichiasis syndrome or as autosomal recessive traits, for example Hennekam 
syndrome.85 Although Milroy disease (OMIM: 153100) is a rare condition, it is one of 
the most frequent causes of congenital primary lymphoedema. It is characterised by 
symmetrical lymphoedema of the lower limbs, particularly the dorsum of the feet and 
ankles but may reach the knees. It typically presents at or shortly after birth, although 
in some cases lymphoedema does not manifest until later in life.86 Additionally, the 
affected areas are prone to decreased rates of healing even following minor trauma 
and the affected skin may become brawny and fibrotic. The impaired lymph drainage 
also predisposes to infection, for example cellulitis, which is also a frequent 
complication in individuals with Milroy disease.86  
 
VEGFR3 was first implicated in Milroy disease when a region of chromosome five was 
linked to inherited lymphoedema cases and the FLT4 locus was chosen as the best 
candidate gene in this region for further investigation.87 A FLT4 missense mutation, 
p.H1035A, was identified in a Milroy patient and in vitro assessment of the mutation 
found that, compared to wild type protein, receptor trans-autophosphorylation was 
inhibited.88 Subsequently, further mutations in FLT4 have been identified and 
approximately seventy percent of Milroy cases have been given a molecular 
diagnosis.89 Importantly, the fifty-seven reported FLT4 mutations identified in Milroy 
disease to date are either missense (n=54) or small in frame deletions (n=3) within the 
kinase domain coding region.90  
 
Full length VEGFR3 harbouring a kinase domain mutation is expressed and 
translocates to the plasma membrane where it can interact with wild type VEGFR3.88 
All mutations identified in Milroy patients thus far have demonstrated decreased 
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catalytic activity and their downstream signalling is also reduced.88 For example, in 
response to VEGFC ligand binding, the MAPK pathways normally activated display 
decreased phosphorylation of sites required for their downstream signalling (Figure 
2b).39, 91-94 Karkkainen et al. also showed that the mutant receptors had greater 
stability and were internalised and degraded at a slower rate compared to wild type 
receptor.95 This altered turnover of mutant VEGFR3 receptors would lead to a greater 
number of mutant receptors available for dimerisation at the plasma membrane; 
thereby reducing the relative amount of wild type VEGFR3 for VEGFC to bind to. Thus, 
evidence suggests that FLT4 mutations in Milroy disease have a dominant negative 
effect as they antagonise the activity of wild type protein.88, 95 
 
 
4. VEGFR3 and congenital heart disease 
4.1. Normal development of the heart and great vessels 
The cardiovascular system develops early during embryogenesis shortly after 
gastrulation with the beginning of cardiogenesis. Figure 4 compares the 
developmental timings of both cardiovascular and lymphovascular systems following 
fertilisation during human and mouse embryogenesis aligned with the established 
Carnegie stages of human embryonic development.96  
 
Heart development begins when progenitor cardiac crescent cells, termed the first 
heart field (FHF), develop from the early mesoderm and form the primary heart tube.97 
Distinct cells from the second heart field (SHF) are then added to both the rostral and 
caudal poles before looping of the tube and the occurrence of further complex 
morphological changes occur to convert the initial in-series circuit to an in-parallel 
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arrangement. Beating of cardiac cells commences at three weeks post-fertilisation in 
humans, well before heart development is complete, followed by the initiation of blood 
flow approximately a week later.  
 
The completion of cardiogenesis occurs when the four chambers of the heart are 
defined at the end of septation.98, 99 Cells originating from both heart fields contribute 
to the atria, whilst FHF-derived cells form the majority of the left ventricle, and SHF-
derived cells the right ventricle and the outflow tract (OFT), which connects the cardiac 
ventricles to the great vessels. Cardiac neural crest cells are migratory mesenchymal 
cells originating from the ectoderm of the dorsal ridge of the neural tube, migrating 
through chiefly the third, fourth and sixth branchial arches towards the heart. They are 
essential, together with mesodermal cardiac cells, for OFT formation, and they also 
contribute significantly to the smooth muscle tunics of the great arteries. The formation 
of arteries, veins and capillaries connecting the heart to the tissues and organs of the 
developing embryo occurs throughout development and life via angiogenesis.100  
 
It is also worth noting that the heart requires its own extensive lymphatic network in 
order to maintain myocardial fluid homeostasis and provide immune surveillance.101 
Cardiac lymphatics are established shortly after the development of the heart 
vasculature during embryogenesis. In mice this is around E12 before coronary 
circulation commences and heart development is complete (Figure 4). The heart’s 
lymphatic network is found in both atria and ventricles extending to at least the mitral 
valve in humans and enriched around the OFT.102 In humans the aortic valve does not 
have any associated lymphatics.103 The specific role of VEGFR3 in cardiac lymphatic 
anatomy and physiology has been reported.104-106 
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Remodelling of cardiac lymphatics has been associated with several diseases 
including ischemic heart disease, myocardial infarction and chronic heart failure. 
Insufficient myocardial drainage via cardiac lymphatics can lead to oedema and 
inflammatory immune responses in cases of infective endocarditis.107 The role cardiac 
lymphatics play in health and disease is an active area of research that is helping 
develop therapeutic treatments for conditions whose cause or degeneration is due to 
dysfunction of normal heart lymphangiogenesis.101, 108 
 
4.2. VEGFR3 variants in congenital heart disease 
CHDs encompass a spectrum of heterogenous phenotypes relating to structural 
defects arising during cardiogenesis. Defects can be singular and localised or a range 
of complex morphological abnormalities can occur simultaneously. Tetralogy of Fallot 
(TOF) is the most common, complex cyanotic CHD with a recorded prevalence of 
approximately 1 in every 2500 live births.109 TOF is considered a malformation of the 
OFT during early cardiac development and is defined by four specific structural 
abnormalities identified postnatally - a ventricular septal defect, anterocephalad 
deviation of the outflow septum with resultant overriding aorta, variable obstruction of 
the right ventricular OFT (pulmonary stenosis) and consequent hypertrophy of the right 
ventricle. Open heart surgery, usually in the first year of life, means up to 90% of TOF 
patients live to the age of 30. However, event-free survival to age 40 is just 25% since 
repercussions of surgery, particularly the development of pulmonary regurgitation, and 
cardiac arrhythmias still cause significant morbidity in adulthood.110-112  
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The genetic basis of TOF is still relatively unknown although approximately 20% of 
cases have been linked with chromosomal anomalies. Most significantly around 15% 
of these syndromic TOF patients have been diagnosed with DiGeorge syndrome (also 
called 22q11.2 deletion syndrome), in which the gene responsible for many of the 
disease manifestations is TBX1 (T box transcription factor 1).113, 114  
 
Through whole exome sequencing (WES) studies of TOF patients by several groups 
there is now robust evidence that rare deleterious variants in FLT4 are a predisposing 
factor for sporadic, non-syndromic TOF.115-119 Our work, evaluating the largest 
nonsyndromic TOF cohort studied to date by WES to date, discovered previously 
unobserved, predicted pathogenic variants in two genes with exome-wide 
significance, NOTCH1 and FLT4.120 The occurrence of FLT4 truncating variants 
(2.4%) was similar to that identified independently by others.115, 116 Looking at a range 
of different CHD probands and parents, FLT4 truncating variants appear to be 
enriched in TOF cases in particular and can be inherited or de novo in an affected 
child.115, 116   
 
The majority of FLT4 variants predisposing to TOF result in truncation of the protein 
coding sequence, either by the introduction of stop codons, frame shift mutations or 
disruption of the conserved splice site regions that dictate the removal of intronic 
sequences from transcripts before translation.120 Missense variants that have never 
been observed in the general population have also been identified in several cases. 
Interestingly, these are predominantly located in the first immunoglobulin-like domains 
of VEGFR3 and are predicted in silico to be highly damaging to protein function.120 In 
contrast, the VEGFR3 mutations that cause Milroy disease are markedly distinct in 
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both mutation type and location from those predisposing to TOF (Figure 5). All Milroy 
FLT4 mutations identified thus far are all missense or in-frame deletions that map to 
the kinase domain89, 90, compared to those identified in TOF cases, which are 
predominantly truncating variants or missense mutations in the extracellular domains.  
 
In addition to the exome sequencing data implicating FLT4 in TOF aetiology, copy 
number variant (CNV) analysis of CHD patients provides further support. Soemedi et 
al.121 identified two TOF cases with CNVs encompassing or adjacent to the FLT4 
locus; one with a de novo duplication of FLT4 and several other genes, and another 
with deletion of the region upstream of the FLT4 locus.121 A separate study identified 
a duplication of FLT4 and two proximal genes in a case of aortic arch anomaly122, 
linking the FLT4 locus and potential genetic regulatory sequences with CHD. 
Intriguingly, two independent TOF cases have been associated with CNVs where only 
the C-terminal coding region of FLT4 is deleted which, like the truncating variants 
identified by WES, could result in expression of a C-terminally truncated protein.118, 122 
These observations further connect the region around the FLT4 locus with CHD; 
however, to date there is no evidence that deletion of the entire FLT4 gene increases 
the incidence of TOF. An enrichment of truncating variants but not deleterious CNVs 
in TOF cases suggests that it is not FLT4 haploinsufficiency that predisposes the 
condition but rather the expression of truncated or mutated VEGFR3 protein during 
embryonic development.  
 
Further supporting the role of FLT4 truncating variants in TOF, a family has been 
recorded where such a mutation has passed through several generations prominently 
increasing the occurrence of TOF in carriers.117, 123 Several other cases have been 
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reported where TOF probands have inherited a FLT4 variant from an unaffected 
parent indicating that the mutant allele has reduced penetrance.116, 120 However, TOF, 
like most CHDs, is only very rarely inherited in a Mendelian fashion, therefore 
susceptibility variants whose penetrance is influenced by other genetic and 
environmental factors are the expected finding in sporadic cases. FLT4 variants 
enriched in TOF cases are all extremely rare or absent in the general population; thus 
far, there has been no evidence from genome-wide association studies (GWAS) that 
common variants in the region predispose to CHD.  
 
VEGFR2 variants have also been associated with CHDs, including TOF118, 124, 125, and 
a meta-analysis of single nucleotide polymorphisms in VEGFA, also a CHD gene, 
identified a variant that increased the incidence of TOF.118, 126 Furthermore, mouse 
embryos modified to solely express Vegfa120 isoform displayed alterations in Vegf 
and Notch signalling and a cardiac phenotype that mimicked TOF.127 Gene expression 
profiling of right ventricular biopsies collected from TOF patients compared to age 
matched controls showed changes in transcript levels for VEGF, VEGFR, PDGF and 
FGF (fibroblast growth factor) family members, though no change in FLT4 was 
reported. Immunohistological staining showed that there was an increase in 
vascularisation of the heart vasculature in TOF cases, but the vessels were stunted 
and could possibly not conduct blood.128 Hence, while VEGFR2 and VEGFA mutations 
are associated with multiple CHD phenotypes, evidence strongly supports a role for 
FLT4 variants primarily in the predisposition to TOF.  
 
 
5. Future directions 
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5.1. Vegfr3 animal models of cardiac and lymphatic development 
The expression of Vegfr3 protein in early embryonic murine hearts has been observed 
in the endocardium at E9.5 and throughout the heart at E12.5 with strong staining of 
specific LECs sprouting proximal to the OFT on the dorsal side.129, 130 Tbx1, a 
transcription factor linked to CHDs including TOF and the cardiovascular 
manifestations of DiGeorge syndrome, is known to regulate Vegfr3 during lymphatic 
vessel development in mice.131 The expression of Tbx1 and Vegfr3 is tightly balanced 
during heart lymphangiogenesis ensuring  the morphology, localisation and number of 
cardiac lymphatic vessels is correct.132  
 
Genetic lineage tracing in Isl1 (insulin gene enhancer protein 1)-Cre reporter mice 
indicated that lymphatic cells surrounding the OFT could arise from the pharyngeal 
mesoderm of the SHF. Isl1 is a key marker of cardiac progenitor cells that form the 
SHF and, interestingly, tracing back to earlier embryonic stages Isl1+ cells were shown 
to overlap with Vegfr3+/Prox1+ cells in the pharyngeal core.133 Endocardial specific 
ablation of Hand2 (heart and neural crest derivatives-expressed protein 2), a known 
CHD gene, in mice, results in cardiac malformations resembling the human condition 
tricuspid atresia and is caused by disruption to Notch-dependent cell-to-cell signalling 
and dysregulation of Vegfr3 function.134 
 
Due to multiple studies pointing to a role for distinct VEGFR3 variants predisposing to 
a human CHD, it is timely to review the various mouse models that give credence to 
a function for the receptor in early cardiac development distinct to that in 
lymphangiogenesis (Table 2).  
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In brief, complete knockout of Vegfr3 results in cardiovascular failure at day E9.5 with 
embryos displaying severe anaemia and cardiac effusion. Angiogenesis occurs but 
the large vessels are disorganised and fluid accumulates in the pericardial cavity 
resulting in lethality.135 Considering the well-established role of Vegfr3 in lymphatic 
development the occurrence of this severe cardiovascular phenotype, before 
commencement of lymphangiogenesis suggests a distinct role for the receptor in early 
cardiovascular development.  
 
A similar phenotype was observed when a conditional K19 (keratin 19 promoter)-Cre 
model was employed to knockout Vegfr3 in the epiblast indicating that the 
cardiovascular phenotype is dependent on Vegfr3 functioning in the embryo proper 
and not due to defects in placental development.136 Intriguingly, mice heterozygous 
for Vegfr3, when compared to homozygous knockouts, do not display abnormal heart 
development or haematopoiesis suggesting one functional copy of Vegfr3 is sufficient 
for normal cardiovascular system development.58 Although there is no obvious 
lymphatic phenotype in these mice and they appear healthy it has been shown that 
the initial number of LECs produced is reduced and peripheral LECs are 
mispatterned.137  
 
Hypomorphic homozygous or heterozygous Vegfr3 mice, in which a neomycin 
cassette has been inserted between the first two exons of the gene causing 
dysregulation of expression but not necessarily altered function, displayed disrupted 
lymphatic system but not cardiovascular system development indicating 
lymphangiogenesis is more sensitive to the relative abundance of Vegfr3 than 
cardiogenesis.136  
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Early cardiovascular system development is also independent of Vegfr3’s 
characterised ligands that are known to be required during lymphangiogenesis. 
Vegfc/Vegfd double knockout mice display abnormal lymphangiogenesis, but normal 
blood vasculature development. Additionally, evidence suggests that Vegfc and Vegfd 
are functionally redundant during lymphangiogenesis136, supporting the notion that 
VEGFR3 has a ligand-independent function in embryonic cardiovascular 
development.   
 
Double heterozygous models of Vegfr3 with either Nrp2 or Foxc2 have abnormal 
lymphatic system development but no embryonic lethality due to cardiovascular 
failure, further indicating that the function of Vegfr3 in heart development is distinct to 
that which mediates LEC maturation and lymphangiogenesis.61, 129 
 
Finally, mice engineered to express versions of Vegfr3 that either could not bind ligand 
(ligand binding domain knockout) or were kinase dead (inactivating missense mutation 
in the kinase domain) also had normal cardiovascular development before and 
lymphatic system dysfunction.138-140  
 
A role for Vegfr3 in valvulogenesis has recently been shown by Fontana et al. during 
cardiac development in zebrafish. Fluid shear stress acting on endocardial cells lining 
the atrioventricular valve leaflet independently activates Notch or Klf2a (Krüppel-like 
Factor 2) signalling and spatial antagonism between the Notch and Vegfr3 pathways 
defines atrioventricular valve morphology.141, 142  
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5.2. Defining the distinct functions of VEGFR3 during development and disease 
The identification of FLT4 as the causal or predisposing genetic factor for two 
unrelated human conditions, Milroy disease and TOF, respectively, highlights the 
distinct roles VEGFR3 plays in development. Since CHD is not considered to be part 
of the Milroy phenotype, and congenital lymphoedema is not considered to be a 
constituent of the TOF phenotype86, 143 how different mutations contribute to disease 
pathology is an intriguing research proposition.  
 
The early embryonic lethality due to cardiac failure of homozygous knockout, or 
conditional epiblast knockout, of Vegfr3 in mice demonstrates the receptor has a 
crucial function in cardiogenesis during early embryonic development. The lack of a 
cardiovascular phenotype in Vegfc/Vegfd double homozygous knockout mice 
suggests this function of Vegfr3 in heart development is different to that during 
lymphangiogenesis since it is not dependent on its activation by such ligands. This is 
supported further by the homozygous mouse models in which Vegfr3’s ligand binding 
domain has been deleted or kinase domain has been inactivated by mutation of an 
amino acid residue that is critical for the receptor’s enzymatic activity. Therefore, we 
can conclude that ligand binding, activation and trans-autophosphorylation of Vegfr3 
that is essential during lymphatic system development is not required for 
cardiogenesis.  
 
Heterozygous Vegfr3 knockout mice have normal cardiovascular system development 
suggesting the function of the receptor during cardiogenesis is not sensitive to the 
level of Vegfr3 protein. This also contrasts with its role in lymphatic system 
development which is sensitive to changes in the level of Vegfr3 expression, as 
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highlighted by the hypomorphic mouse model. This reemphasises that 
haploinsufficiency as a disease mechanism of the FLT4 variants that greatly increase 
the risk of TOF is unlikely, and that the disease pathogenesis is instead related to the 
expression of mutated VEGFR3 protein. Further supporting this is the extraordinarily 
low occurrence of truncating FLT4 variants observed in exome and genome 
sequences from the Genome Aggregation Database (gnomAD) of over 100,000 
people. Indeed it has been calculated from the gnomAD database that FLT4 is very 
intolerant to such loss of function variants.144  
 
Vegfr3 mouse genetic models, that do not have a cardiovascular phenotype all still 
express the receptor with an N-terminal targeting sequence and C-terminal tail. In 
contrast, the truncations seen in TOF all result in coding sequences that are shorter 
from the C-terminus whilst retaining their N-terminal signal sequence. Therefore, it is 
tempting to suggest that in TOF it is expression and dysfunction of C-terminally 
truncated mutant VEGFR3 proteins that inappropriately modulates cellular functions 
early in development, leading to disrupted cardiogenesis. The truncated VEGFR3 
proteins could act through aberrant interaction with other proteins such as wild type 
VEGFR3, proteins of the exocytotic pathway, coreceptors, ligands or an as yet 
uncharacterised or pathological binding partner. Such an interaction could occur in 
endocardial cells, vascular endothelial cells or cardiac LECs and only be disruptive to 
heart development in particular physiological environments or genetic backgrounds.  
 
VEGFR3 can modulate vascular permeability in blood vessel endothelial cells, where, 
even though it is weakly expressed, it plays a physiological role controlling the 
expression of the major angiogenesis regulator VEGFR2.145 VEGFR2 has a role in 
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cardiomyocyte hypertrophy through paracrine signalling between endothelial cells and 
cardiomyocytes during physiological myocardial growth. This is mediated by the 
VEGFA-VEGFR2-DLL4(delta-like protein 4)-NOTCH signalling axis.146 If the FLT4 
truncating mutations observed in TOF cases disrupted this function of VEGFR2 in cells 
of the SHF, where FLT4 expression has been reported133, then that could lead to 
abnormal cardiac development. A role for VEGFR2 in formation of the arterial pole of 
the heart from the early pharyngeal mesoderm should also be considered in TOF 
aetiology.100  
 
The FLT4 gene also shows intolerance to missense variants in the gnomAD database 
(FLT4 Z-score = 3.73).144 The FLT4 missense mutations identified in a small number 
of TOF cases that are previously unobserved and predicted to be highly damaging to 
protein function are almost all located in the receptor’s extracellular domain and could 
be acting in a similar manner to the truncating mutations.120 Of note, the de novo 
mutation, C51W, identified in a TOF proband (Figure 5), would disrupt the C51-C111 
disulfide bond that is important for the structure of the first immunoglobulin-like domain 
of VEGFR332 and would possibly disrupt proper ligand binding.   
 
Though it is now clear that VEGFR3 has a role in both Milroy disease and TOF, there 
are undoubtedly significant gaps in our knowledge regarding the different functions of 
this multifaceted receptor. Identifying the cell types important for Vegfr3’s role in 
cardiogenesis could be done by employing conditional mouse models that could also 
be used to assess when during development Vegfr3 is required, for example, in early 
or late OFT progenitor cells. If generation of a knock-in mouse harbouring a truncated 
version of Vegfr3 had a phenotype mimicking TOF it would be an extremely powerful 
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tool for delineating the mechanism by which heart malformations occur in disease. 
Another approach would be to generate human embryonic stem cells harbouring 
different FLT4 TOF variants using the most up to date genome editing tools followed 
by experiments assessing for changes in their differentiation to relevant 
developmental cell types such as cardiomyocytes, neural crest cells or an endothelial 
lineage.  
 
 
6. Summary 
The functions of VEGFR3 in lymphangiogenesis, angiogenesis and cardiogenesis and 
the link to human conditions of distinct genetic variants of the gene make it an enticing 
avenue for future research. However, due to the complicated nature of these different 
processes and the difficulty separating them experimentally, researchers must 
carefully plan the techniques they adopt to elucidate both the physiological functions 
and disease mechanisms associated with VEGFR3.  
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Table 1. Overview of VEGFR family members in health and disease. Summary of 
the three VEGFRs and their known physiological roles and associated pathologies.  
 
Figure 1. Structures, interactions, physiological roles and associated diseases 
of VEGFR family members. Schematic showing the interactions of the three 
VEGFRs with each other and their ligands at the plasma membrane. Their expression 
pattern, physiological roles and pathologies associated with their levels or dysfunction 
are also shown. Ig, immunoglobulin-like domain; SS, disulphide bond.  
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Figure 2. VEGFR3 signalling during lymphangiogenesis and Milroy disease. 
Ligand binding and VEGFR3 homodimerisation during lymphangiogenesis results in 
activation of downstream signalling pathways in LECs or precursor endothelial cells 
(a). The dominant negative mutations of the kinase domain of VEGFR3 in Milroy 
disease result in reduction of downstream signalling following ligand binding due to 
loss of autophosphorylation and thus consequent disruption of lymphangiogenesis (b). 
*, mutations in the kinase domain of VEGFR3 that inactivate the receptor’s catalytic 
activity; pY, phosphotyrosine; SS, disulphide bond; description of protein 
abbreviations in main text.   
 
Figure 3. VEGFR3 functions with VEGFR2 and NRP2. Heterodimerisation of 
VEGFR3 and VEGFR2 and activation by VEGFA or VEGFC regulates multiple 
biological processes in endothelial and endothelial-derived cell lines (a). Association 
of VEGFR3 homodimers with NRP2 and activation of VEGFR3 by its cognate ligands 
and NRP2 by VEGFA modulates VEGFR3 function (b). SS, disulphide bond.    
 
Figure 4. Developmental timing of cardiovascular and lymphovascular system 
development. Developmental timings in both human and mouse of cardiovascular 
and lymphovascular development, aligned with the Carnegie stages of embryonic 
development. For references see main text.    
 
Figure 5. Comparison of VEGFR3 mutations between Milroy disease and TOF. 
The characterised VEGFR3 mutations known to cause Milroy disease (missense or 
small in frame deletions, blue dots) are compared to those that predispose to TOF 
(missense, predicted highly damaging to protein function, scaled combined 
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annotation-dependent depletion score ≥20; previously unobserved in the general 
population, absent from the gnomAD database, green dots; or truncating, i.e. 
nonsense, frameshifts and splice donor or acceptor site nucleotide changes, red dots). 
The location of the de novo point mutant C51W is indicated beneath. References in 
the main text. Ig, immunoglobulin-like domain; SP, signal peptide; TMD, 
transmembrane domain.   
 
Table 2. Cardiovascular and lymphovascular phenotypes of Vegfr3 mouse 
models. Summary of mouse genetic models modulating expression of Vegfr3 alone 
or in combination with other genes and their resulting cardiovascular and 
lymphovascular phenotypes.  
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Receptor Physiological roles Associated pathologies References 
VEGFR1  
> activation and chemotaxis of macrophages and monocytes  
> embryonic vasculogenesis 
> haematopoesis 
> VEGFA/VEGFR2 antagonism 
> Alzheimer’s disease 
> cancer cell survival 
> inflammation and inflammatory disorders 
> metastasis 
> preeclampsia 
> tumour angiogenesis 
23, 26, 28 
VEGFR2  
> angiogenesis 
> endothelial cell migration, proliferation and survival 
> haematopoesis 
> vascular permeability 
> vasculogenesis 
> Alzheimer’s disease 
> capillary infantile haemangioma 
> coronary artery disease 
> tumourigenesis  
24, 26, 30, 31 
VEGFR3  
> angiogenesis 
> lymphangiogenesis 
> vasculogenesis  
> cancer cell proliferation 
> Milroy disease (hereditary lymphoedema type IA) 
> congenital heart disease  
25, 88, 120 
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Genotype Mouse model Lymphatic phenotype Cardiovascular phenotype References 
Vegfr3-/- Vegfr3 global knockout > embryonic lethal E9.5 
> large vessels misplaced 
> cardiac effusion 
> severe anaemia 
> fluid in pericardial cavity 
> abnormal haematopoiesis 
135 
Vegfr3+/- Vegfr3 heterozygous knockout 
> number of initial LECs reduced 
> peripheral LECs mispatterned 
> primary thoracic duct diameter reduced 
> normal 58, 137 
Vegfr3lx/lx;K19cre Vegfr3 conditional epiblast knockout > embryonic lethal E10.5 > similar to global knockout 136 
Vegfr3+/I1053F 
 
(Chy mouse model) 
heterozygous Vegfr3 kinase dead 
> around half have oedema 
> occasionally lymph vessels and a lymph sac are observed 
> normal 139, 140 
Vegfr3neo/neo Vegfr3 hypomorph 
> embryos swollen at E14.5 
> lack of lymphatic vasculature 
> perinatal lethality 
> blood vasculature appears normal 136 
Vegfr3+/neo Vegfr3 heterozygous hypomorph 
> embryos swollen at E14.5 
> only display remnants of lymphatic vessels 
> reduced viability 
> blood vasculature appears normal 136 
Vegfr3I1053F/I1053F Vegfr3 kinase dead 
> inhibited lymphatic growth and development 
> disrupted lymph sac formation 
> no lymphatic sprouting 
> normal blood vasculature 138 
Vegfr3ΔLBD/ΔLBD Vegfr3 ligand binding domain deletion 
> oedema 
> lymph sac forms but no lymphatic vessel growth 
> normal blood vasculature 138 
Vegfc-/-;Vegfd-/- double knockout of Vegfr3’s ligands 
> lymphatic development fails 
> embryonic lethal E16.5 
> normal blood vasculature  136 
Foxc2+/-;Vegfr3+/- heterozygous knockout of Vegfr3 and Foxc2 
> oedema at E14.5 
> enlarged lymphatic capillaries 
> abnormally patterned lymphatic vessels at E17.5 
> lymphatic capillaries develop smooth muscle cells 
> normal 129 
Nrp2+/-; Vegfr3+/- heterozygous knockout of Vegfr3 and Nrp2 
> abnormal lymphatic development 
> decreased lymphatic vessel branching 
> normal 61 
Table 2
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Figure 3
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Figure 4
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Figure 5
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